Recent Updates
Recently added Catalysts

TERN-501

Phase 2

NASH - Nonalcoholic Steatohepatitis | Small molecule | Infectious Disease |Terns Pharmaceuticals, Inc.|Last Updated: Mar 11, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment162
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05415722DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic SteatohepatitisPHASE2 COMPLETED 162Jun 1, 2022Jul 1, 2023Mar 11, 2025 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
TERN-501DRUGInvestigational drug
TERN-101DRUGInvestigational drug
PlaceboOTHERMatching placebo
Unlock Study Design Details